Reference priceEUR €577.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Zeva lin kit |
|---|---|
| Manufacturer | Spectrum Pharmaceuticals B.V. |
| Prescription required | Yes |
Zeva lin kit 3.2mg/2ml(ibritumomab tiuxetan (111In)) (Ibritumomab Tiuxetan(genetical recombination))
Ibritumomab Tiuxetan(genetical recombination)
Description
Zeva lin kit 3.2mg/2ml(ibritumomab tiuxetan (111In)) (Ibritumomab Tiuxetan(genetical recombination)) is a medicine catalog record in the MediPriceHub database. Active ingredient: Ibritumomab Tiuxetan(genetical recombination). Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Spectrum Pharmaceuticals B.V.. Therapeutic category: Medicine Library > Oncology Medicines > Non-Hodgkin's Lymphomas. Pack information: 3.2 / 2 1. Origin country or market: Japan. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
Zevalin is a CD20-directed radiotherapeutic antibody administered as part of the Zevalin therapeutic regimen indicated for the treatment of adult patients with: relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL) . previously untreated follicular NHL who achieve a partial or complete response to first-line chemotherapy .How to Use
Use Ibritumomab Tiuxetan(genetical recombination) under the supervision of a qualified healthcare professional. Use it only according to the approved label and the instructions of a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: Ibritumomab Tiuxetan(genetical recombination). Pack size: 3.2 / 2 1. Pack unit: unit. Manufacturer: Spectrum Pharmaceuticals B.V.. Origin country: Japan. Source category: Medicine Library > Oncology Medicines > Non-Hodgkin's Lymphomas. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.Diese Angaben dienen nur als Referenz. Lassen Sie sich vor der Anwendung eines Medikaments von medizinischem Fachpersonal beraten.